Drug interactions in patients infected with human immunodeficiency virus.
Patients with AIDS who are receiving optimal medical care, including combination therapy with antiretroviral agents and more effective prophylaxis and therapy for opportunistic infections and neoplasms, are surviving longer. However, the potential for drug interactions in these patients is increased because many of the currently used antibiotics and antiviral agents have profound effects on the hepatic cytochrome P-450 enzyme system, on renal tubular function, and on bone marrow function. In this AIDS Commentary, Dr. Piscitelli and colleagues have succinctly reviewed the current state of our knowledge regarding the potential for additive or synergistic drug interactions that can result in enhanced toxicity or, alternatively, augmented therapeutic benefit. Information on these interactions will become more important as more intensive and effective therapy becomes available for persons with far-advanced infection due to human immunodeficiency virus type 1.
Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
S C
SC
Piscitelli
C
C
Flexner
J R
JR
Minor
M A
MA
Polis
H
H
Masur
D000042:Absorption; D000863:Antacids / Q000009:adverse effects; D018926:Anti-Allergic Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D019380:Anti-HIV Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects; D000935:Antifungal Agents / Q000009:adverse effects; D000994:Antitrichomonal Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects; D016207:Cytokines / Q000502:physiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007668:Kidney / Q000502:physiology; D008099:Liver / Q000378:metabolism; D009294:Narcotics / Q000009:adverse effects; D010599:Pharmacokinetics
D000863:Antacids; D018926:Anti-Allergic Agents; D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D000994:Antitrichomonal Agents; D000998:Antiviral Agents; D003276:Contraceptives, Oral; D016207:Cytokines; D004791:Enzyme Inhibitors; D009294:Narcotics